Sera Prognostics (NASDAQ:SERA) Cut to "Sell" at Wall Street Zen

Key Points

• Sera Prognostics has been downgraded from a "hold" to a "sell" rating by Wall Street Zen, indicating a negative outlook from analysts.
• Despite posting better-than-expected earnings of ($0.16) EPS, the company reported a significant net margin loss of 30,306.48% and revenue of only $0.02 million for the last quarter.
• Insider selling has occurred, with CEO Zhenya Lindgardt selling over 23,000 shares, representing a 2.66% decrease in their ownership of the company.

Sera Prognostics (NASDAQ:SERA - Get Free Report) was downgraded by equities research analysts at Wall Street Zen from a "hold" rating to a "sell" rating in a research note issued to investors on Saturday.

Sera Prognostics Stock Up 2.5%

Shares of SERA traded up $0.06 during midday trading on Friday, reaching $2.29. 18,788 shares of the stock were exchanged, compared to its average volume of 228,140. Sera Prognostics has a 12-month low of $1.37 and a 12-month high of $9.13. The firm has a 50 day simple moving average of $2.44 and a 200-day simple moving average of $3.17. The company has a market cap of $86.08 million, a price-to-earnings ratio of -2.68 and a beta of 0.99.

Sera Prognostics (NASDAQ:SERA - Get Free Report) last posted its quarterly earnings results on Wednesday, August 6th. The company reported ($0.16) earnings per share for the quarter, topping analysts' consensus estimates of ($0.21) by $0.05. The company had revenue of $0.02 million during the quarter, compared to the consensus estimate of $0.05 million. Sera Prognostics had a negative return on equity of 45.86% and a negative net margin of 30,306.48%. Research analysts expect that Sera Prognostics will post -0.96 earnings per share for the current fiscal year.

Insider Activity at Sera Prognostics

In other Sera Prognostics news, CEO Zhenya Lindgardt sold 23,042 shares of the business's stock in a transaction dated Monday, June 9th. The stock was sold at an average price of $1.43, for a total value of $32,950.06. Following the completion of the transaction, the chief executive officer directly owned 844,209 shares of the company's stock, valued at approximately $1,207,218.87. The trade was a 2.66% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. In the last ninety days, insiders sold 38,014 shares of company stock worth $55,268. 15.80% of the stock is owned by company insiders.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the business. BNP Paribas Financial Markets acquired a new position in Sera Prognostics in the fourth quarter valued at about $28,000. Sanders Morris Harris LLC grew its stake in Sera Prognostics by 4.0% in the first quarter. Sanders Morris Harris LLC now owns 94,200 shares of the company's stock valued at $347,000 after acquiring an additional 3,600 shares during the period. Rhumbline Advisers lifted its holdings in shares of Sera Prognostics by 10.7% in the first quarter. Rhumbline Advisers now owns 39,970 shares of the company's stock valued at $147,000 after purchasing an additional 3,869 shares in the last quarter. Bank of New York Mellon Corp lifted its holdings in shares of Sera Prognostics by 3.6% in the first quarter. Bank of New York Mellon Corp now owns 135,582 shares of the company's stock valued at $499,000 after purchasing an additional 4,670 shares in the last quarter. Finally, Wells Fargo & Company MN lifted its holdings in shares of Sera Prognostics by 55.2% in the fourth quarter. Wells Fargo & Company MN now owns 13,192 shares of the company's stock valued at $107,000 after purchasing an additional 4,691 shares in the last quarter. 54.64% of the stock is owned by institutional investors and hedge funds.

Sera Prognostics Company Profile

Sera Prognostics, Inc, a women's health diagnostic company, discovers, develops, and commercializes biomarker tests for improving pregnancy outcomes in the United States. The company develops PreTRM test, a blood-based biomarker test to predict the risk of spontaneous preterm birth in singleton pregnancies.